AVALO THERAPEUTICS, INC. Construction Contractor, Receivable, Excluding Contract Retainage
AVALO THERAPEUTICS, INC. (AVTX) had Construction Contractor, Receivable, Excluding Contract Retainage of $208.20 thousand as of 2019-09-30, per its 10-Q filed 2019-11-14.
Discontinued › Notes › and Others
us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms · last filed 2019-11-14
- 2019-09-30: Construction Contractor, Receivable, Excluding Contract Retainage $208.20K.
- 2019-06-30: Construction Contractor, Receivable, Excluding Contract Retainage $143.01K.
- 2019-03-31: Construction Contractor, Receivable, Excluding Contract Retainage $5.53M.
- 2018-12-31: Construction Contractor, Receivable, Excluding Contract Retainage $5.47M.
| Period end | Construction Contractor, Receivable, Excluding Contract Retainage |
|---|---|
| 2019-09-30 | $208.20K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $143.01K 10-Q · filed 2019-08-08 |
| 2019-03-31 | $5.53M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $5.47M 10-Q · filed 2019-11-14 |
| 2018-09-30 | $6.26M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $88.02K 10-Q · filed 2018-08-09 |
| 2018-03-31 | $55.58K 10-Q · filed 2018-05-11 |
| 2017-12-31 | $427.24K 10-K · filed 2019-03-18 |
| 2016-12-31 | $0.00 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |